PDCD1 and neoplasm: There is also growing interest in identifying the immune-active properties of the tumor microenvironment (TME) that constitute an immunologically “hot” tumor in responders to PD-1/PD-L1 blockade, in contrast to the immunologically “cold” tumor [5, 6].